Circulating anti-Ro/SSA-antibodies and risk of heart rate-corrected QT interval prolongation: a meta-analysis
Pietro Enea Lazzerini, Mark Markovich Melamud, Evgeny Alexandrovich Ermakov, Vadim Vyacheslavovich Kon’kov, Valentina Nikolaevna Buneva, Riccardo Accioli, Alessandra Cartocci, Anna Cantore, Viola Salvini, Decoroso Verrengia, Maurizio Acampa, Pier Leopoldo Capecchi, Mohamed BoutjdirAbstract
Backgrounds
Accumulating evidence indicates that anti-Ro/Sjögren’s syndrome-related antigen A(SSA)-antibodies, specifically the anti-Ro/SSA-52kD subtype, can promote heart rate-corrected QT interval(QTc) prolongation by inhibiting the hERG-K+ channel. However, the numerous clinical studies published over the past two decades yielded conflicting results.
Objective
This meta-analysis aims at pooling the available data to provide clarity on this clinically relevant issue.
Methods
A systematic review was performed for clinical studies comparing QTc in anti-Ro/SSA-positive vs. -negative subjects. Standardized mean differences(SMDs) and odds ratios(ORs) were compared using random effects models. The risk of bias was assessed using RoBANS2, Egger's test and contour-enhanced funnel plots.
Results
Twenty-five studies were included, pooling 2,122 anti-Ro/SSA-positive and 8,865 anti-Ro/SSA-negative subjects. Overall, anti-Ro/SSA-positivity is associated with a longer QTc(SMD=0.36[0.18–0.53], p<0.001), and a >2-times higher risk of QTc prolongation(2.24[1.54-3.27], p<0.001). Several sub-analyses supported and refined these findings. Specifically, in anti-Ro/SSA-positive patients with unselected CTD, QTc absolute values are higher(SMD=0.57[0.20-0.94], p=0.002) and QTc prolongation occurs more frequently(OR=7.62[2.50-23.21], p<0.001) than in negative patients; furthermore, QTc prolongation is also more common in SLE patients with circulating anti-Ro/SSA-antibodies than in those without(OR=1.86[1.19–2.90], p=0.006). Finally, in anti-Ro/SSA-52kD-positive subjects, the QTc is longer compared to the negative ones(SMD=0.43[0.15–0.71], p=0.002).
Conclusions
This meta-analysis supports the conclusion that circulating anti-Ro/SSA-antibodies per se represents a significant risk factor for QTc prolongation. However, the presence of several conflicting studies suggests that a more accurate investigation of specific factors, such as the impact of individual antibody subtype levels(anti-52kD/anti-60kD), will be critical to fully clarify the topic and its implications in clinical practice.